{"organizations": [], "uuid": "261826a5f2cea9290ca875bf45468305da9e4176", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 1, "shares": 1, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "https://fm.cnbc.com/applications/cnbc.com/resources/img/editorial/2017/09/18/104716606-GettyImages-492437706-eli-lilly.1910x1000.jpg", "site_section": "", "section_title": "", "url": "https://www.cnbc.com/2018/04/02/pharmas-cheap-stocks-spell-investment-opportunity-for-traders-jp-morgan.html", "country": "US", "domain_rank": 767, "title": "Pharma's cheap stocks spell investment opportunity for traders: JP Morgan", "performance_score": 0, "site": "cnbc.com", "participants_count": 0, "title_full": "", "spam_score": 0.223, "site_type": "news", "published": "2018-04-02T20:24:00.000+03:00", "replies_count": 0, "uuid": "261826a5f2cea9290ca875bf45468305da9e4176"}, "author": "Thomas Franck", "url": "https://www.cnbc.com/2018/04/02/pharmas-cheap-stocks-spell-investment-opportunity-for-traders-jp-morgan.html", "ord_in_thread": 0, "title": "Pharma's cheap stocks spell investment opportunity for traders: JP Morgan", "locations": [], "entities": {"persons": [{"name": "chris schott", "sentiment": "none"}], "locations": [{"name": "france", "sentiment": "none"}, {"name": "us", "sentiment": "none"}, {"name": "fegersheim", "sentiment": "none"}], "organizations": [{"name": "jp morgan cnbc.com frederick florin", "sentiment": "negative"}, {"name": "pharma", "sentiment": "negative"}, {"name": "eli lilly", "sentiment": "none"}, {"name": "j.p. morgan", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Pharmaceutical stocks are trading at one of their largest discounts to the market in nearly 10 years, J.P. Morgan told clients Monday.\n\"This underperformance reflects ongoing drug pricing concerns, many of which are either well reflected in estimates or unlikely to come to fruition for the foreseeable future,\" analyst Chris Schott wrote. \"We see an attractive opportunity to revisit an admittedly out-of-favor sector with a mix of new launch driven sales/earnings upside and capital deployment/M&A representing potential catalysts for the space.\"", "external_links": [], "published": "2018-04-02T20:24:00.000+03:00", "crawled": "2018-04-02T20:25:43.020+03:00", "highlightTitle": ""}